Selected research
Industry Research
Anti-VEGF Intravitreal Drugs Industry Research Report 2026
Market perspective
The global Anti-VEGF Intravitreal Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Anti-VEGF Intravitreal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Anti-VEGF Intravitreal Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Anti-VEGF Intravitreal Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Anti-VEGF Intravitreal Drugs include Qilu Pharma, Chengdu Kanghong Pharmaceutical, Samsung Bioepis, Roche, Regeneron Pharmaceuticals, Novartis, Coherus BioSciences, Biogen and Biocon Biologics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Anti-VEGF Intravitreal Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anti-VEGF Intravitreal Drugs Market by Company
Qilu Pharma
Chengdu Kanghong Pharmaceutical
Samsung Bioepis
Roche
Regeneron Pharmaceuticals
Novartis
Coherus BioSciences
Biogen
Biocon Biologics
Anti-VEGF Intravitreal Drugs Segment by Type
Aflibercept
Brolucizumab
Faricimab
Conbercept
Ranibizumab
Other
Anti-VEGF Intravitreal Drugs Segment by Application
Age-related Macular Degeneration
Retinal Vein Occlusion
Diabetic Macular Edema
Other
Anti-VEGF Intravitreal Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-VEGF Intravitreal Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-VEGF Intravitreal Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-VEGF Intravitreal Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Anti-VEGF Intravitreal Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Anti-VEGF Intravitreal Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Anti-VEGF Intravitreal Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Aflibercept
- Brolucizumab
- Faricimab
- Conbercept
- Ranibizumab
- Other
Applications
- Age-related Macular Degeneration
- Retinal Vein Occlusion
- Diabetic Macular Edema
- Other
Companies covered
- Qilu Pharma
- Chengdu Kanghong Pharmaceutical
- Samsung Bioepis
- Roche
- Regeneron Pharmaceuticals
- Novartis
- Coherus BioSciences
- Biogen
- Biocon Biologics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Anti-VEGF Intravitreal Drugs Market Size (2021-2032)
- 2.2.2 Global Anti-VEGF Intravitreal Drugs Sales (2021-2032)
- 2.2.3 Global Anti-VEGF Intravitreal Drugs Market Average Price (2021-2032)
- 2.3 Anti-VEGF Intravitreal Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Aflibercept
- 2.3.3 Brolucizumab
- 2.3.4 Faricimab
- 2.3.5 Conbercept
- 2.3.6 Ranibizumab
- 2.3.7 Other
- 2.4 Anti-VEGF Intravitreal Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Age-related Macular Degeneration
- 2.4.3 Retinal Vein Occlusion
- 2.4.4 Diabetic Macular Edema
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Anti-VEGF Intravitreal Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Anti-VEGF Intravitreal Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Anti-VEGF Intravitreal Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Anti-VEGF Intravitreal Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Anti-VEGF Intravitreal Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Anti-VEGF Intravitreal Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Anti-VEGF Intravitreal Drugs, Product Type & Application
- 3.8 Global Manufacturers of Anti-VEGF Intravitreal Drugs, Established Date
- 3.9 Global Anti-VEGF Intravitreal Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Qilu Pharma
- 4.1.1 Qilu Pharma Company Information
- 4.1.2 Qilu Pharma Business Overview
- 4.1.3 Qilu Pharma Anti-VEGF Intravitreal Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Qilu Pharma Anti-VEGF Intravitreal Drugs Product Portfolio
- 4.1.5 Qilu Pharma Recent Developments
- 4.2 Chengdu Kanghong Pharmaceutical
- 4.2.1 Chengdu Kanghong Pharmaceutical Company Information
- 4.2.2 Chengdu Kanghong Pharmaceutical Business Overview
- 4.2.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product Portfolio
- 4.2.5 Chengdu Kanghong Pharmaceutical Recent Developments
- 4.3 Samsung Bioepis
- 4.3.1 Samsung Bioepis Company Information
- 4.3.2 Samsung Bioepis Business Overview
- 4.3.3 Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Samsung Bioepis Anti-VEGF Intravitreal Drugs Product Portfolio
- 4.3.5 Samsung Bioepis Recent Developments
- 4.4 Roche
- 4.4.1 Roche Company Information
- 4.4.2 Roche Business Overview
- 4.4.3 Roche Anti-VEGF Intravitreal Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Roche Anti-VEGF Intravitreal Drugs Product Portfolio
- 4.4.5 Roche Recent Developments
- 4.5 Regeneron Pharmaceuticals
- 4.5.1 Regeneron Pharmaceuticals Company Information
- 4.5.2 Regeneron Pharmaceuticals Business Overview
- 4.5.3 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product Portfolio
- 4.5.5 Regeneron Pharmaceuticals Recent Developments
- 4.6 Novartis
- 4.6.1 Novartis Company Information
- 4.6.2 Novartis Business Overview
- 4.6.3 Novartis Anti-VEGF Intravitreal Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Novartis Anti-VEGF Intravitreal Drugs Product Portfolio
- 4.6.5 Novartis Recent Developments
- 4.7 Coherus BioSciences
- 4.7.1 Coherus BioSciences Company Information
- 4.7.2 Coherus BioSciences Business Overview
- 4.7.3 Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Coherus BioSciences Anti-VEGF Intravitreal Drugs Product Portfolio
- 4.7.5 Coherus BioSciences Recent Developments
- 4.8 Biogen
- 4.8.1 Biogen Company Information
- 4.8.2 Biogen Business Overview
- 4.8.3 Biogen Anti-VEGF Intravitreal Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Biogen Anti-VEGF Intravitreal Drugs Product Portfolio
- 4.8.5 Biogen Recent Developments
- 4.9 Biocon Biologics
- 4.9.1 Biocon Biologics Company Information
- 4.9.2 Biocon Biologics Business Overview
- 4.9.3 Biocon Biologics Anti-VEGF Intravitreal Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Biocon Biologics Anti-VEGF Intravitreal Drugs Product Portfolio
- 4.9.5 Biocon Biologics Recent Developments
5 Global Anti-VEGF Intravitreal Drugs Market Scenario by Region
- 5.1 Global Anti-VEGF Intravitreal Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Anti-VEGF Intravitreal Drugs Sales by Region: 2021-2032
- 5.2.1 Global Anti-VEGF Intravitreal Drugs Sales by Region: 2021-2026
- 5.2.2 Global Anti-VEGF Intravitreal Drugs Sales by Region: 2027-2032
- 5.3 Global Anti-VEGF Intravitreal Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Anti-VEGF Intravitreal Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Anti-VEGF Intravitreal Drugs Revenue by Region: 2027-2032
- 5.4 North America Anti-VEGF Intravitreal Drugs Market Facts & Figures by Country
- 5.4.1 North America Anti-VEGF Intravitreal Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Anti-VEGF Intravitreal Drugs Sales by Country (2021-2032)
- 5.4.3 North America Anti-VEGF Intravitreal Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Anti-VEGF Intravitreal Drugs Market Facts & Figures by Country
- 5.5.1 Europe Anti-VEGF Intravitreal Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Anti-VEGF Intravitreal Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Anti-VEGF Intravitreal Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Anti-VEGF Intravitreal Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Anti-VEGF Intravitreal Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Anti-VEGF Intravitreal Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Anti-VEGF Intravitreal Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Anti-VEGF Intravitreal Drugs Market Facts & Figures by Country
- 5.7.1 South America Anti-VEGF Intravitreal Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Anti-VEGF Intravitreal Drugs Sales by Country (2021-2032)
- 5.7.3 South America Anti-VEGF Intravitreal Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Anti-VEGF Intravitreal Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Anti-VEGF Intravitreal Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Anti-VEGF Intravitreal Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Anti-VEGF Intravitreal Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Anti-VEGF Intravitreal Drugs Sales by Type (2021-2032)
- 6.1.1 Global Anti-VEGF Intravitreal Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Anti-VEGF Intravitreal Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Anti-VEGF Intravitreal Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Anti-VEGF Intravitreal Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Anti-VEGF Intravitreal Drugs Sales by Application (2021-2032)
- 7.1.1 Global Anti-VEGF Intravitreal Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Anti-VEGF Intravitreal Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Anti-VEGF Intravitreal Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Anti-VEGF Intravitreal Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Anti-VEGF Intravitreal Drugs Value Chain Analysis
- 8.1.1 Anti-VEGF Intravitreal Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Anti-VEGF Intravitreal Drugs Production Mode & Process
- 8.2 Anti-VEGF Intravitreal Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Anti-VEGF Intravitreal Drugs Distributors
- 8.2.3 Anti-VEGF Intravitreal Drugs Customers
9 Global Anti-VEGF Intravitreal Drugs Analyzing Market Dynamics
- 9.1 Anti-VEGF Intravitreal Drugs Industry Trends
- 9.2 Anti-VEGF Intravitreal Drugs Industry Drivers
- 9.3 Anti-VEGF Intravitreal Drugs Industry Opportunities and Challenges
- 9.4 Anti-VEGF Intravitreal Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst